GSK's Witty calls for an R&D renaissance

GSK CEO Andrew Witty (photo) wants everyone to know that he gets it. R&D productivity in the industry is awful, industrializing the creative process failed. And now Big Pharma has to rely on partnering with biotechs and academics to get its mojo back, recognizing that this is as much art as science. Pharma companies, meanwhile, will have to do more deals like Viiv Healthcare, which pooled its HIV products and pipelines with Pfizer. That's Witty's bottom line in an editorial he wrote for the Economist. Column

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.